Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protoco

/ --
- RESILIENT Protocol captures Encyclopedic information from tumors and uses Artificial Intelligence (AI) to optimize treatments;
- Objective Response and Disease Control Comparable to or better than most Immunotherapy options;
- Unique Ultra-personalised combination of drugs already approved for cancer;
- RESILIENT Protocol commercially launched
The data of the RESILIENT Trial is published in the peer revived oncology journal 'Oncotarget' (https://doi.org/10.18632/oncotarget.27188)

Related Links
https://doi.org/10.18632/oncotarget.27188
https://doi.org/10.1093/annonc/mdz268.061
https://datarpgx.com/encyclopedic-tumor-analysis-exacta/